Blog
RSS FeedPosted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based ...
Posted by Michael Wonder on 24 Mar 2021
Seqirus ready to reinforce Canada's influenza pandemic preparedness plans
23 March 2021 - Health Canada's approval of Foclivia (an adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine) meets key requirement ...